IP Library › Granted Patent US 10,913,775
Granted Patent B2
US 10,913,775 · App. 15/937,567 · Granted Feb 9, 2021

Treating cancer with viral nucleic acid

Inventors: Stephen James Russell (Rochester, MN); Elizabeth J. Kelly (Rochester, MN); Elizabeth M. Hadac (Oronoco, MN)
Assignee: Mayo Foundation for Medical Education and Research
C07K14/005A61K35/768C12N7/00C12N2770/32311C12N2770/32332C12N2770/32611C12N2770/32632C12N2840/102Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,913,775
App. No.
15/937,567
Granted
Feb 9, 2021
Kind
B2
Abstract

This document provides methods and materials related to the use of nucleic acid coding for viruses to reduce the number of viable cancer cells within a mammal. For example, methods for using infectious nucleic acid to treat cancer, engineered viral nucleic acid, methods for making engineered viral nucleic acid, methods for identifying infectious nucleic acid for treating cancer, methods and materials for controlling virus-mediated cell lysis, and methods and materials for assessing the control of virus-mediated cell lysis are provided.

Claims (3)

1. A composition comprising an effective amount of RNA coding for a picornavirus in the absence of (a) picornavirus particles and (b) host cells comprising said RNA, wherein said effective amount of said RNA is effective to cause cancer regression within a mammal, wherein when said composition is administered to said mammal having cancer cells, said cancer cells present within said mammal undergo cell lysis as a result of synthesis of picornavirus particles from said RNA and said synthesis of picornavirus particles progresses into a picornavirus infection within said mammal, thereby resulting in cancer regression, wherein said effective amount is about 9.92×10 11 (4 μg) or more virus genome copies.

2. The composition of claim 1 , wherein said picornavirus is a coxsackievirus.

3. The composition of claim 1 , wherein said picornavirus is Coxsackievirus A21.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2018
From: RUSSELL, STEPHEN J.; KELLY, ELIZABETH J.; HADAC, ELIZABETH M.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 045647/0667 →
Continuity (6)
Continuation 14792178 · Jul 6, 2015
Continuation 13952343 · Jul 26, 2013
Continuation 12528047
Provisional Application 61009968 · Jan 4, 2008
Provisional Application 60902200 · Feb 20, 2007
Related Publication 20180215794A1 · Aug 2, 2018